Antiretroviral prescribing patterns in treatment-naïve patients in the United States

AIDS Patient Care and STDs

Volumn 24, Issue 2, 2010, Pages 79-85

  McKinnell, James A ^a   Willig, James H ^a   Westfall, Andrew O ^b   Nevin, Christa ^a   Allison, Jeroan J ^c   Raper, James L ^a   Mugavero, Michael J ^a   Saag, Michael S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRESCRIPTION; UNITED STATES;

ALABAMA; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, UNIVERSITY; HUMANS; MALE; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 77149152220     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0220     Document Type: Article

References (21)

1. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937.
2. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-1883.
3. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
4. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000;14:397-403.
5. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
7. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-1861.
8. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008;197:1145-1155.
9. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006;42:1003-1010.
10. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951-1960.
11. Gazzard B, DeJesus E, Campo R, et al. The combination of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) has significantly greater responses vs fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients: A 24 week preliminary analysis [Abstract H1137c]. Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, D.C: 2004.
12. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008;300: 555-570.
13. The Antiretroviral Therapy Cohort Committee. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
14. Institute of Medicine (U.S.). Division of Health Care Services. Committee on the Future of Primary Care., Donaldson MS. Primary Care: America's Health in a New Era. Washington, D.C: National Academy Press, 1996.
15. Barr M, Ginsburg J. The advanced medical home: A patient-centered, physician-guided model of health care. In: American College of Physicians: Current Policy Papers, 2006.
16. Redesigning the practice model for general internal medicine. A proposal for coordinated care: A policy monograph of the Society of General Internal Medicine. J Gen Intern Med 2007;22:400-409.
17. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-529.
18. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1-17; quiz CE11-14.
19. Reddy S, Sabatino S. Coordination of Care: Missed Opportunity? Synthesis of the Literature on Care Coordination. ABIM Foundation Summer Forum. August 2007.
20. Saag MS. Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection? Clin Infect Dis 2007;45(Suppl 4):S261-265.
21. Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men - Five U.S. cities, June 2004-April 2005. MMWR Morb Mortal Wkly Rep 2005;54:597-601.